A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Crohn's Disease Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00446433
• Other study ID #: CC-5013-CD-001
• Status: Completed
• Phase: Phase 2
• First received: March 7, 2007
• Last updated: November 30, 2016
• Start date: March 2002
• Est. completion date: December 2003

Study information

• Verified date: November 2016
• Source: Celgene Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: December 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male and female subjects > 12 and < 75 years of age.

2. Adolescent and adult female subjects must be of non-childbearing potential (hysterectomy) or be using one highly effective method (e.g., IUD, hormonal contraception, tubal ligation) of birth control during the entire study. Abstinence will be considered an acceptable method of birth control for adolescent females aged 12-17 years who are not sexually active and who the investigator feels will be compliant with this requirement for the 12-week treatment period. Female subjects who are post-menopausal must have had 24 continuous months of amenorrhea.

3. Negative pregnancy test for females of child bearing potential.

4. A history of Crohn's Disease (CD) of greater than 1-year duration diagnosed and documented by standard clinical, radiographic, endoscopic, histopathological criteria.

5. Signs and symptoms of moderately severe CD as defined by a Crohn's Disease Activity Index (CDAI) score of > 220 and < 400.

6. Normal thyroid function as documented by normal TSH (thyroid stimulating hormone).

7. The subject's treatment for CD must be unchanged, as described below:

The start date of the medications listed below must be at least 4 weeks prior to randomization, and the dose must have been unchanged for at least 2 weeks prior to that visit. Medication doses may be decreased but not increased throughout the study. If not currently using these agents, the stop date of any previous treatment with these agents must be at least 4 weeks prior to randomization. The medications are:

• oral or systemic corticosteroids

• metronidazole (Flagyl®)

• sulfasalazine

• oral mesalamine

• oral olsalazine

• topical rectal therapy with corticosteroids or mesalamine

8. The start date of the medications listed below must be at least 3 months (12 weeks) prior to randomization, and the dose must have been unchanged for at least 4 weeks. Medication doses may be decreased but not increased throughout the study. If not currently using these agents, the stop date of any previous treatment with these agents must be at least 6 weeks prior to randomization. The medications are:

• azathioprine (AZA)

• 6-mercaptopurine (6 MP)

• methotrexate

9. Subject's screening laboratory test results must meet the following criteria:

• hemoglobin > 8.5 g/dL.

• white blood cells (WBC) > 3.5 x 109 / L.

• neutrophils > 1.5 x 109/L and lymphocytes >0.5 x 109/L.

• platelets > 100 x 109 / L.

• bilirubin, alanine transaminase (ALT), aspartate transaminase (AST) , and alkaline phosphate levels must not be above two times the upper limit of the normal range.

• serum albumin > 3.2 mg /dL for adults (18-75) and serum albumin > 2.8 mg/dL for adolescents between the ages of 12-17.

• serum creatinine < 2.0 mg/dL

10. Subjects must be able to adhere to the study visit schedule and other protocol requirements.

11. The subject must understand and voluntarily sign an informed consent document. Adolescent subjects under 18 years of age must have parent/guardian consent as evidenced by a signature on the consent form as well as their own assent, as evidenced by signature on the consent form.

12. The subject must be at least 25 kg (55 lbs).

Exclusion Criteria:

1. Pregnancy or lactation.

2. Predisposition to cardiac arrhythmias and history of clinically significant cardiac disease.

3. Diagnosis of ulcerative colitis.

4. CD that is limited to the stomach and proximal small intestine.

5. Known severe fixed symptomatic stenosis or stricture of the small or large intestine.

6. Current evidence of bowel obstruction, or history within the 3 months preceding randomization confirmed with objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the bowel proximal to the stricture observed upon barium enema or an inability to traverse the stricture at endoscopy.

7. Subjects who have undergone a proctocolectomy or total colectomy with ileorectal anastomosis; segmental colectomy is permitted.

8. Colostomy or ileostomy.

9. Subjects with fulminant disease requiring parenteral steroid treatment, hospitalization, or felt to be in imminent need of surgery, i.e. toxic megacolon, active gastrointestinal bleeding, history of significant ulcer disease and/or esophagitis, peritonitis, intestinal obstruction, perforation, or intra-abdominal abscess requiring surgical drainage.

10. Subjects requiring intravenous nutritional support with total parenteral nutrition (TPN)/partial parenteral nutrition (PPN) that provides > 50 % of total daily caloric intake.

11. Subjects in whom enteral nutrition with elemental or semi-elemental formula comprises more than 50% of their total daily caloric intake. For adolescents between the ages of 12-17, subjects in whom enternal nutrition with elemental or semi-elemental formula comprises more the 75% of their total daily caloric intake.

12. Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine (including thyroid as documented by an abnormal TSH), pulmonary, cardiac, neurological, or cerebral disease, including the following specific exclusions: uncontrolled diabetes, unstable ischemic heart disease, uncontrolled or recent seizures, autoimmune diseases not related to inflammatory bowel diseases, chronic respiratory insufficiency, or recent cerebral vascular accident (within 2 months of randomization).

13. Serious infections or history of opportunistic infections; less serious infections within 3 months of randomization, such as acute upper respiratory tract infections (colds) or uncomplicated urinary tract infection are permitted at the discretion of the Investigator. The following are specific exclusions:

• Chronic hepatitis B and C

• Documented HIV infection, ARC (AIDS related complex), AIDS, or immune deficiency.

14. Stool examination positive for enteric pathogens (including Clostridium difficile),pathogenic ova, or parasites.

15. Concomitant or recent medication use as follows:

• Treatment with any other therapeutic agent targeted at reducing TNF-a, e.g., CC-1088, thalidomide, cyclosporine, or pentoxifylline within 4 weeks of randomization, and mycophenolate (Cellcept), infliximab (Remicadeä), Enbrelä, or FK506 (Tacrolimus) within 8 weeks of randomization

• Treatment with interleukin-2 or -10 or other immunomodifier agent within 24 weeks of randomization.

• Requirement of systemic corticosteroid therapy for other disease(s), e.g., asthma. Inhaled steroids for treating asthma are acceptable for this protocol.

• Subjects receiving anticoagulant therapy (other than a total daily aspirin dose of 325 mg or less).

• Subjects having received non CD-directed antibiotic therapy within 2 weeks of randomization. CD-directed antibiotic therapy, for example with ciprofloxacin or metronidazole, is acceptable provided the dose has been stable for the 2 weeks prior to randomization.

• Subjects who have received an investigational drug within 30 days of randomization.

16. Subjects with a history of malignancy, except basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ.

17. Dysplasia (low-grade or high-grade) of the colon/small bowel within the last 5 years prior to screening.

18. Subjects who, in the judgment of the Investigator, are unwilling or unable to comply with all the protocol-related assessments and procedures, including completion of a daily diary.

19. History of alcohol or other drug abuse within 1 year of randomization, or any conditions associated with poor compliance.

20. Subjects in whom multiple venipunctures are not feasible due to poor tolerability or lack of easy access.

21. Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Drug:
• CC-5013

Locations

Country	Name	City	State
France	Hopital Saint Louis	Paris
Israel	Rambam Hospital	Haifa
Israel	Department of Medicine A, Liver & Gastroenterology Units	Jerusalem
Israel	Department of Gastroenterology and Hepatology	Tel-Hashomer
United Kingdom	Department of Gastroenterology	Bristol
United Kingdom	Addenbrookes Hospital	Cambridge
United Kingdom	Department of Medicine	Cardiff
United Kingdom	Department of Gastroenterology	Dartford	Kent
United Kingdom	Department of Gastroenterology	London
United Kingdom	Department of Gastroenterology	London
United Kingdom	Department of Gastroenterology	London
United Kingdom	Department of Gastroenterology	Manchester
United Kingdom	St. Mark's Hospital	Middlesex
United Kingdom	Department of Gastroentroerology	Newcastle
United States	Advanced Clinical Research Institute	Anaheim	California
United States	Wake Research Associates	Raleigh	North Carolina
United States	Springfield Clinic	Springfield	Illinois
United States	Advanced Clinical Therapeutics	Tucson	Arizona
United States	Washington Hospital Center Physicians Office Building	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Celgene Corporation

Countries where clinical trial is conducted

United States,  France,  Israel,  United Kingdom, 

References & Publications (1)

Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther. 2007 Aug 1;26(3):421-30. — View Citation